Bucket Trial

• Bucket Trials group patients by the molecular alterations in their tumors, not by the tumor’s origin site.
• These trials test a single targeted therapy or combination across different cancer types that share a specific genetic mutation.
• The primary goal is to identify effective treatments for specific biomarkers, accelerating drug development.
• They are a cornerstone of precision medicine, moving away from a “one-size-fits-all” approach.
• This design offers efficiency by allowing researchers to study a drug’s efficacy across multiple indications simultaneously.

What is a Bucket Trial?

A Bucket Trial refers to a type of clinical trial design that deviates from traditional methods by grouping patients based on the genetic or molecular characteristics of their tumors, rather than the anatomical site where the cancer originated. This innovative approach is central to precision oncology, where treatments are tailored to the specific genetic profile of a patient’s cancer. The Bucket trial meaning and explanation centers on the idea of collecting patients with diverse cancer types into “buckets” if their tumors share a common molecular alteration, such as a specific gene mutation or protein overexpression, which a targeted therapy is designed to address.

Traditionally, clinical trials have been organized by cancer type (e.g., breast cancer trials, lung cancer trials). However, as scientific understanding of cancer genetics has advanced, it has become clear that cancers from different organs can share similar molecular drivers, while cancers within the same organ can have vastly different genetic profiles. Bucket trials leverage this understanding, allowing researchers to test a single drug against a specific molecular target across a range of cancer types, provided they exhibit the targetable alteration. This design is particularly valuable for identifying treatments for rare mutations that might not be feasible to study in traditional, site-specific trials due to small patient populations.

The design of a Bucket Trial often involves:

• Molecular Screening: Patients undergo comprehensive genomic profiling to identify specific molecular alterations in their tumors.
• Stratification: Patients are then assigned to different “buckets” based on the identified molecular alteration, regardless of their cancer’s primary site.
• Targeted Therapy: All patients within a specific bucket receive the same targeted therapy designed to inhibit the shared molecular alteration.

Function and Purpose of Bucket Trials

How do bucket trials function? These trials operate by enrolling patients who, despite having different types of cancer, all possess a specific molecular biomarker that a particular investigational drug aims to target. For instance, a drug designed to inhibit a BRAF V600E mutation could be tested in patients with melanoma, colorectal cancer, or lung cancer, as long as their tumors carry that specific mutation. This allows for a more efficient assessment of a drug’s efficacy against a particular molecular target across a broader spectrum of diseases. The Bucket trial definition and purpose is fundamentally about accelerating the development of targeted therapies and identifying biomarkers that predict response to treatment, thereby matching the right drug to the right patient.

The primary purpose of Bucket Trials is to streamline the drug development process, particularly for targeted therapies. By grouping patients based on molecular commonalities, these trials can:

• Increase Efficiency: They allow for the simultaneous evaluation of a drug across multiple cancer types, potentially reducing the time and resources needed for drug approval for various indications.
• Address Rare Cancers/Mutations: They provide a viable pathway for studying therapies for rare cancer types or uncommon genetic mutations that would be difficult to investigate in traditional, site-specific trials due to limited patient numbers.
• Advance Precision Medicine: They contribute significantly to the paradigm shift towards personalized cancer treatment, where therapeutic decisions are guided by the unique molecular landscape of an individual’s tumor.

According to the National Cancer Institute (NCI), the increasing complexity of cancer and its genetic heterogeneity necessitates innovative trial designs like bucket trials to efficiently test new targeted agents. This approach helps to overcome the limitations of traditional trials, especially given the growing number of identified actionable molecular targets. By focusing on the underlying biology rather than the anatomical location, Bucket Trials are pivotal in delivering more effective and personalized treatments to patients.